Cardioprotective Effects of Hydrogen Sulfide and Its Potential Therapeutic Implications in the Amelioration of Duchenne Muscular Dystrophy Cardiomyopathy

被引:2
|
作者
Loboda, Agnieszka [1 ]
Dulak, Jozef [1 ]
机构
[1] Jagiellonian Univ Krakow, Fac Biochem Biophys & Biotechnol, Dept Med Biotechnol, Gronostajowa 7 St, PL-30387 Krakow, Poland
关键词
Duchenne muscular dystrophy; DMD; cardiomyopathy; iPSC-CM; induced pluripotent stem cell-derived cardiomyocytes; hydrogen sulfide; H2S; DOXORUBICIN-INDUCED CARDIOTOXICITY; CONVERTING ENZYME-INHIBITORS; GLUCOSE-INDUCED APOPTOSIS; INDUCED HEART-FAILURE; S-PROPARGYL-CYSTEINE; K-ATP CHANNELS; REPERFUSION INJURY; MYOCARDIAL-INFARCTION; INDUCED INFLAMMATION; CARDIAC DYSFUNCTION;
D O I
10.3390/cells13020158
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Hydrogen sulfide (H2S) belongs to the family of gasotransmitters and can modulate a myriad of biological signaling pathways. Among others, its cardioprotective effects, through antioxidant, anti-inflammatory, anti-fibrotic, and proangiogenic activities, are well-documented in experimental studies. Cardiorespiratory failure, predominantly cardiomyopathy, is a life-threatening complication that is the number one cause of death in patients with Duchenne muscular dystrophy (DMD). Although recent data suggest the role of H2S in ameliorating muscle wasting in murine and Caenorhabditis elegans models of DMD, possible cardioprotective effects have not yet been addressed. In this review, we summarize the current understanding of the role of H2S in animal models of cardiac dysfunctions and cardiac cells. We highlight that DMD may be amenable to H2S supplementation, and we suggest H2S as a possible factor regulating DMD-associated cardiomyopathy.
引用
收藏
页数:30
相关论文
共 50 条
  • [21] Therapeutic potential of hiPSC-derived cardiomyocytes for Duchenne Muscular Dystrophy
    Wang, Ruchen
    Perlingeiro, Rita
    van Berlo, Jop
    PHYSIOLOGY, 2024, 39
  • [22] Therapeutic potential of miRNAs in Duchenne muscular dystrophy and other neuromuscular diseases
    Xia, Yuxing
    JOURNAL OF PHYSIOLOGY-LONDON, 2021, 599 (05): : 1377 - 1378
  • [23] Laminin-111: A Potential Therapeutic Agent for Duchenne Muscular Dystrophy
    Goudenege, Sebastien
    Lamarre, Yann
    Dumont, Nicolas
    Rousseau, Joel
    Frenette, Jerome
    Skuk, Daniel
    Tremblay, Jacques P.
    MOLECULAR THERAPY, 2010, 18 (12) : 2155 - 2163
  • [24] Cardiomyopathy in Duchenne Muscular Dystrophy and the Potential for Mitochondrial Therapeutics to Improve Treatment Response
    Gandhi, Shivam
    Sweeney, H. Lee
    Hart, Cora C.
    Han, Renzhi
    Perry, Christopher G. R.
    CELLS, 2024, 13 (14)
  • [25] The Cardioprotective Effects of Hydrogen Sulfide in Heart Diseases: From Molecular Mechanisms to Therapeutic Potential
    Shen, Yaqi
    Shen, Zhuqing
    Luo, Shanshan
    Guo, Wei
    Zhu, Yi Zhun
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2015, 2015
  • [26] Hydrogen sulfide attenuates skeletal muscle abnormalities in a murine model of Duchenne muscular dystrophy
    Loboda, A.
    Myszka, M.
    Mucha, O.
    Hajok, K.
    Jakubczak, E.
    Wasniowska, U.
    Dulak, J.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [27] Macrophage plasticity in Duchenne muscular dystrophy: a nexus of pathological remodelling with therapeutic implications
    Petrof, Basil J.
    JOURNAL OF PHYSIOLOGY-LONDON, 2022, 600 (15): : 3455 - 3464
  • [28] Antisense-mediated modulation of splicing Therapeutic implications for duchenne muscular dystrophy
    Aartsma-Rus, Annemieke
    RNA BIOLOGY, 2010, 7 (04) : 453 - 461
  • [29] A state-of-the-art review of tamoxifen as a potential therapeutic for duchenne muscular dystrophy
    Botti, Valeria
    Menzel, Olivier
    Staedler, Davide
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [30] Faecal microbiota transplantation: a potential novel therapeutic avenue for Duchenne muscular dystrophy
    Timpani, C.
    Debrincat, D.
    Van der Beek, J.
    Eri, R.
    Diwakarla, S.
    McQuade, R.
    Rybalka, E.
    NEUROMUSCULAR DISORDERS, 2024, 43